Evidence map›Paper›PMID 37928527›Full record

ArticleFrontiers in immunology2023

Alexander Kirchmair, Niloofar Nemati, Giorgia Lamberti, Marcel Trefny, Anne Krogsdam, Anita Siller, Paul Hörtnagl, Petra Schumacher, Sieghart Sopper, Adolf Sandbichler and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Lypd6b depletion promotes CD8Nature communications · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Alexander KirchmairInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Niloofar NematiInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Giorgia LambertiInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Marcel TrefnyDepartment of Biomedicine, Cancer Immunology, University and University Hospital of Basel, Basel, Switzerland.
Anne KrogsdamInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Anita SillerCentral Institute for Blood Transfusion and Immunology, Tirol Kliniken GmbH, Innsbruck, Austria.
Paul HörtnaglCentral Institute for Blood Transfusion and Immunology, Tirol Kliniken GmbH, Innsbruck, Austria.
Petra SchumacherCore Facility FACS Sorting, University Clinic for Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
Sieghart SopperCore Facility FACS Sorting, University Clinic for Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
Adolf SandbichlerInstitute of Zoology, University of Innsbruck, Innsbruck, Austria.
Alfred ZippeliusDepartment of Biomedicine, Cancer Immunology, University and University Hospital of Basel, Basel, Switzerland.
Bart GhesquièreLaboratory of Applied Mass Spectrometry, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Zlatko TrajanoskiInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Universität Innsbruck · ATInnsbruck Medical University · ATTirol Kliniken · ATUniversity Hospital of Basel · CHVIB-KU Leuven Center for Cancer Biology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Naïve T cells remain in an actively maintained state of quiescence until activation by antigenic signals, upon which they start to proliferate and generate effector cells to initiate a functional immune response. Metabolic reprogramming is essential to meet the biosynthetic demands of the differentiation process, and failure to do so can promote the development of hypofunctional exhausted T cells. Methods: Here we used 13C metabolomics and transcriptomics to study the metabolism of CD8+ T cells in their complete course of differentiation from naïve over stem-like memory to effector cells and in exhaustion-inducing conditions. Results: The quiescence of naïve T cells was evident in a profound suppression of glucose oxidation and a decreased expression of ENO1, downstream of which no glycolytic flux was detectable. Moreover, TCA cycle activity was low in naïve T cells and associated with a downregulation of SDH subunits. Upon stimulation and exit from quiescence, the initiation of cell growth and proliferation was accompanied by differential expression of metabolic enzymes and metabolic reprogramming towards aerobic glycolysis with high rates of nutrient uptake, respiration and lactate production. High flux in anabolic pathways imposed a strain on NADH homeostasis, which coincided with engagement of the proline cycle for mitochondrial redox shuttling. With acquisition of effector functions, cells increasingly relied on glycolysis as opposed to oxidative phosphorylation, which was, however, not linked to changes in mitochondrial abundance. In exhaustion, decreased effector function concurred with a reduction in mitochondrial metabolism, glycolysis and amino acid import, and an upregulation of quiescence-associated genes, TXNIP and KLF2, and the T cell suppressive metabolites succinate and itaconate. Discussion: Overall, these results identify multiple metabolic features that regulate quiescence, proliferation and effector function, but also exhaustion of CD8+ T cells during differentiation. Thus, targeting these metabolic checkpoints may be a promising therapeutic strategy for both prevention of exhaustion and promotion of stemness of anti-tumor T cells.

Indexed as

CD8-Positive T-LymphocytesLymphocyte ActivationBiological TransportCell DifferentiationDown-RegulationHumans13C tracer analysisdifferentiationexhaustionimmunometabolismRNA sequencingstem cell memory cells

Identifiers

PMID37928527
PMCPMC10620935
OpenAlexW4387779317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.